How important a factor is the outcome of the presidential election for the direction of stocks? Not as important as a COVID-19 vaccine, according to Goldman Sachs. With this in mind, today’s article highlights two therapeutics companies focused on battling neurodegenerative diseases where analysts at Goldman see significant upside potential. For these two stocks – both of which have earned “Strong Buy” consensus analyst ratings, CLICK HERE.
